Diabetic Hypertension - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 0 PAGES: 17

More Info
									Diabetic Hypertension – Pipeline Review, H2 2011




         Diabetic Hypertension - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1419IDB

                                                                                          Publication Date: October 2011




Diabetic Hypertension – Pipeline Review, H2 2011                                                                 GMDHC1419IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Diabetic Hypertension – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 3
      List of Figures .................................................................................................................................................................................................... 3
Introduction .............................................................................................................................................................................................................. 4
      Global Markets Direct Report Coverage ............................................................................................................................................................. 4
Diabetic Hypertension Overview ............................................................................................................................................................................... 5
Therapeutics Development ....................................................................................................................................................................................... 6
      An Overview of Pipeline Products for Diabetic Hypertension .............................................................................................................................. 6
Diabetic Hypertension Therapeutics under Investigation by Universities/Institutes .................................................................................................... 8
Mid Clinical Stage Products ...................................................................................................................................................................................... 9
      Comparative Analysis ........................................................................................................................................................................................ 9
Diabetic Hypertension Therapeutics - Products under Investigation by Universities/Institutes ..................................................................................10
      Assessment by Combination Products ..............................................................................................................................................................11
      Assessment by Molecule Type ..........................................................................................................................................................................12
Drug Profiles ...........................................................................................................................................................................................................14
      Olmesartan + Amlodipine - Drug Profile ............................................................................................................................................................14
            Product Description ....................................................................................................................................................................................14
            Mechanism of Action...................................................................................................................................................................................14
            R&D Progress .............................................................................................................................................................................................14
      Candesartan/Valsartan + Amlodipine - Drug Profile...........................................................................................................................................15
            Product Description ....................................................................................................................................................................................15
            Mechanism of Action...................................................................................................................................................................................15
            R&D Progress .............................................................................................................................................................................................15
Appendix .................................................................................................................................................................................................................16
      Methodology .....................................................................................................................................................................................................16
            Coverage ..............................................
								
To top